Dimerix slipped toward $0.19 after volatile trading driven by its Phase 3 ACTION3 trial. The biotech continues to swing on sentiment as investors react to clinical updates, balancing long-term DMX-200 hopes against no-revenue uncertainty and regulatory timelines.
Dimerix shares plunged 35–40% amid heavy selling and uncertainty around clinical updates, worsened by weak biotech sentiment. Further downside depends on results and the funding outlook, though volatility in early-stage biotech stocks suggests a potential for sharp rebounds.
